For the year ending 2025-12-31, ARQT made $376,072K in revenue. -$16,178K in net income. Net profit margin of -4.30%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenues | 376,072 | 196,542 | 59,606 | 3,686 |
| Cost of sales | 36,695 | 19,128 | 4,987 | 754 |
| Research and development | 77,051 | 76,420 | 110,575 | 182,435 |
| Selling, general and administrative | 274,553 | 229,391 | 185,145 | 122,124 |
| Total operating expenses | 388,299 | 324,939 | 300,707 | 305,313 |
| Loss from operations | -12,227 | -128,397 | -241,101 | -301,627 |
| Interest income | 8,897 | - | - | - |
| Interest expense | 12,083 | 27,168 | - | - |
| Other income (expense), net | 443 | 16,173 | 11,786 | 5,821 |
| Interest expense | - | - | 29,712 | 15,652 |
| Loss before income taxes | -14,970 | -139,392 | -259,027 | - |
| Total other income (expense) | - | - | - | -9,831 |
| Provision for income taxes | 1,171 | 647 | 3,113 | - |
| Net loss | -16,141 | -140,039 | -262,140 | -311,458 |
| Unrealized gain on marketable securities | -206 | 219 | 1,186 | -831 |
| Foreign currency translation adjustment | 169 | -230 | -96 | - |
| Total other comprehensive income (loss) | -37 | -11 | 1,090 | - |
| Comprehensive loss | -16,178 | -140,050 | -261,050 | -312,289 |
| Basic EPS | -0.13 | -1.16 | -3.78 | -5.66 |
| Diluted EPS | -0.13 | -1.16 | -3.78 | -5.66 |
| Basic Average Shares | 127,234,000 | 120,957,633 | 69,305,487 | 55,032,265 |
| Diluted Average Shares | 127,234,000 | 120,957,633 | 69,305,487 | 55,032,265 |
Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT)